U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C24H21N3O5S
Molecular Weight 463.506
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZ-11645373

SMILES

[O-][N+](=O)C1=CC(=CC=C1)C2=CC=C(OCC(CCC3=CC=NC=C3)N4C(=O)CSC4=O)C=C2

InChI

InChIKey=VQEHBLGYANQWEA-UHFFFAOYSA-N
InChI=1S/C24H21N3O5S/c28-23-16-33-24(29)26(23)21(7-4-17-10-12-25-13-11-17)15-32-22-8-5-18(6-9-22)19-2-1-3-20(14-19)27(30)31/h1-3,5-6,8-14,21H,4,7,15-16H2

HIDE SMILES / InChI

Molecular Formula C24H21N3O5S
Molecular Weight 463.506
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

AZ11645373 is a potent and selective antagonist of human P2X7, that was developed by Astra Pharmaceuticals Ltd for treatment pain. AZ11645373 Inhibits BzATP-mediated calcium influx and inhibits ATP-mediated IL-1β release in vitro. AZ11645373 in addition to its well-characterized ability to inhibit the pro-inflammatory action of ATP demonstrates a broad P2X7 receptor-independent anti-inflammatory activity against chemically different types of inflammatory agonists. This type of polypharmacology may be especially effective for treatment of inflammatory disorders due to a combination of P2X7-dependent and P2X7-independent anti-inflammatory mechanisms. In other words, AZ11645373 has a potential to induce several beneficial effects including inhibition of inflammasome-mediated generation of IL-1β and IL-18, inhibition of inflammatory pain.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Human umbilical vein endothelial cells were used for activity evaluation. Cells were preincubated with a solution of AZ11645373 in EBM-2/2% FCS/20 mM HEPES for 20 min followed by addition of OxPAPC (30 to 40 μg/ml) in the same medium. After incubation for 6 h at 37 °C, the medium was removed and RNAzol®RT (Molecular Research Center Inc.; Cincinnati, OH, USA) was added and total RNA was isolated. Concentrations of RNA were determined using a DS-11+Spectophotometer (DeNovix; Wilmington, DE, USA).
Substance Class Chemical
Record UNII
XY4SZP4C72
Record Status Validated (UNII)
Record Version